Volcano: Learning To Thrive In A Declining PCI Market
Long used to a growing market driven by favorable demographics, cardiovascular companies are facing a declining PCI market, in the US and Europe at least, and are forced to shift their strategies to adapt. Volcano, for one, is articulating a new way to approach this declining market.
You may also be interested in...
Doc Payments For Coronary Stenting Will Drop Next Year, But Will Better Reflect Procedure Complexity
New coding structure for coronary stenting recognizes more complex procedure with higher levels of Medicare reimbursement, but overall physician payments for percutaneous coronary interventions will go down in 2013.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."